CD274 and neoplasm: Immunotherapy biomarkers of response are currently intensively studied, and to date they include programmed cell death ligand 1 (PD-L1) expression, high tumor mutational burden (TMB), and high microsatellite instability (MSI), which has been reported to occur in 28% of CUP cases [157,161,185].